KR20150047602A - 인슐린 유사 성장 인자 1(igf-1)을 증강 또는 억제시키는 모노클로날 항체 - Google Patents

인슐린 유사 성장 인자 1(igf-1)을 증강 또는 억제시키는 모노클로날 항체 Download PDF

Info

Publication number
KR20150047602A
KR20150047602A KR1020157007804A KR20157007804A KR20150047602A KR 20150047602 A KR20150047602 A KR 20150047602A KR 1020157007804 A KR1020157007804 A KR 1020157007804A KR 20157007804 A KR20157007804 A KR 20157007804A KR 20150047602 A KR20150047602 A KR 20150047602A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
substitution
antigen
Prior art date
Application number
KR1020157007804A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 클레몬스
로라 마일리
마이클 나소
프랜시스 제이. 카
티모시 디. 존스
시몬 윌리엄 킨
Original Assignee
더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 filed Critical 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐
Publication of KR20150047602A publication Critical patent/KR20150047602A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020157007804A 2012-08-31 2013-08-30 인슐린 유사 성장 인자 1(igf-1)을 증강 또는 억제시키는 모노클로날 항체 KR20150047602A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261695409P 2012-08-31 2012-08-31
US61/695,409 2012-08-31
PCT/US2013/057484 WO2014036385A1 (en) 2012-08-31 2013-08-30 Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (igf-1)

Publications (1)

Publication Number Publication Date
KR20150047602A true KR20150047602A (ko) 2015-05-04

Family

ID=50184409

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157007804A KR20150047602A (ko) 2012-08-31 2013-08-30 인슐린 유사 성장 인자 1(igf-1)을 증강 또는 억제시키는 모노클로날 항체

Country Status (13)

Country Link
US (3) US9073996B2 (de)
EP (1) EP2890716A4 (de)
JP (1) JP2015533117A (de)
KR (1) KR20150047602A (de)
CN (1) CN104768975A (de)
AU (1) AU2013308568A1 (de)
BR (1) BR112015004119A2 (de)
CA (1) CA2882757A1 (de)
HK (1) HK1213904A1 (de)
IL (1) IL237279A0 (de)
MX (1) MX2015002465A (de)
RU (1) RU2015106333A (de)
WO (1) WO2014036385A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8187595B2 (en) 2004-05-07 2012-05-29 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
EP2730282A1 (de) * 2007-11-08 2014-05-14 The General Hospital Corporation Verfahren und Zusammensetzung zur Behandlung von Proteinurie-Erkrankungen
HUE13746964T2 (hu) 2012-02-06 2020-01-28 Inhibrx Inc CD47 antitestek és alkalmazási eljárásaik
EP2890716A4 (de) 2012-08-31 2016-06-08 Univ North Carolina Monoklonale antikörper zur verstärkung oder hemmung des insulinähnlichen faktors 1 (igf-1)
SG10201800492PA (en) 2013-04-29 2018-03-28 Hoffmann La Roche Human fcrn-binding modified antibodies and methods of use
JP6778110B2 (ja) 2014-01-15 2020-10-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 改善されたプロテインＡ結合を有するＦｃ領域バリアント

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1297815C (en) 1985-06-07 1992-03-24 Barry S. Coller Fibrinogen blocking monoclonal antibody
DK0554284T3 (da) 1990-10-24 1997-01-06 Allelix Biopharma Peptid-baserede hæmmere af Hiv-replikation
JP3353209B2 (ja) * 1992-04-03 2002-12-03 ジェネンテク，インコーポレイテッド αｖβ３インテグリンに対する抗体
GB9317423D0 (en) 1993-08-21 1993-10-06 Imp Cancer Res Tech Monoclonal antibodies
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US6590079B2 (en) 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US6596850B1 (en) 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
US6875741B2 (en) 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
AU768295B2 (en) * 1998-11-03 2003-12-04 Centocor Inc. Modified antibodies and antibody fragments with increased duration of activity
WO2000055181A1 (en) 1999-03-15 2000-09-21 The General Hospital Corporation Methods of modulating cell attachment and migration
US6531580B1 (en) 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
WO2005035753A1 (ja) * 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
US8187595B2 (en) 2004-05-07 2012-05-29 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
WO2005117936A2 (en) 2004-05-07 2005-12-15 The University Of North Carolina At Chapel Hill Method for enhancing or inhibiting insulin-like growth factor-i
US8093360B2 (en) 2006-09-28 2012-01-10 Elusys Therapeutics, Inc. Antibodies that bind B. anthracis exotoxin, formulations thereof, and methods of use
US8323654B2 (en) * 2007-05-14 2012-12-04 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
EP2025685B1 (de) * 2007-08-15 2013-06-19 Canadian Blood Services Monoklonale Antikörper gegen BETA3-Integrine
EP2730282A1 (de) 2007-11-08 2014-05-14 The General Hospital Corporation Verfahren und Zusammensetzung zur Behandlung von Proteinurie-Erkrankungen
CA2779958A1 (en) 2008-11-06 2010-05-14 University Of Miami Role of soluble upar in the pathogenesis of proteinuric kidney disease
EP2890716A4 (de) 2012-08-31 2016-06-08 Univ North Carolina Monoklonale antikörper zur verstärkung oder hemmung des insulinähnlichen faktors 1 (igf-1)

Also Published As

Publication number Publication date
US9587024B2 (en) 2017-03-07
CN104768975A (zh) 2015-07-08
RU2015106333A (ru) 2016-10-27
HK1213904A1 (zh) 2016-07-15
US9073996B2 (en) 2015-07-07
EP2890716A4 (de) 2016-06-08
US20140072568A1 (en) 2014-03-13
CA2882757A1 (en) 2014-03-06
BR112015004119A2 (pt) 2017-08-08
IL237279A0 (en) 2015-04-30
EP2890716A1 (de) 2015-07-08
WO2014036385A1 (en) 2014-03-06
JP2015533117A (ja) 2015-11-19
US20150259422A1 (en) 2015-09-17
US20180016340A1 (en) 2018-01-18
AU2013308568A1 (en) 2015-04-09
MX2015002465A (es) 2015-11-06

Similar Documents

Publication Publication Date Title
CN112654638B (zh) 一种抗Claudin18.2抗体及其应用
KR102537651B1 (ko) 항 gpr20 항체 및 항 gpr20 항체-약물 콘쥬게이트
CN107001472B (zh) 对cd73具有特异性的结合分子及其用途
JP5340724B2 (ja) 神経成長因子アンタゴニストを投与することによって骨関節炎疼痛を治療するための方法とそれを含有する組成物
US11981740B2 (en) BAFF-R antibodies and uses thereof
KR20180128028A (ko) 항-il-33 항체, 그의 조성물, 방법 및 용도
US9587024B2 (en) Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (IGF-1)
KR20160078499A (ko) 종양 괴사 인자-유사 리간드 1a 특이적 항체 및 그의 조성물 및 용도
KR20190015747A (ko) Baff-r 표적 키메라 항원 수용체-변형된 t 세포 및 그 용도
KR20140116525A (ko) 항cxcr3 항체
KR102492057B1 (ko) 골 형태형성 단백질 6(ｂｍｐ6)의 억제제를 사용한 질병의 치료 방법
JP2017537084A (ja) 抗エンドグリン抗体及びその用途
US20100260769A1 (en) Endosialin binding molecules
US20230118517A1 (en) Methods of treating multiple myeloma
EP3821006A2 (de) Antikörper spezifisch für folat-rezeptor alpha
JP2014534965A (ja) コンパニオン診断を用いた乳癌の治療
US20220041749A1 (en) Antibodies specific to muc18
KR101667227B1 (ko) 인간화된 ｋ33ｎ 단일 클론 항체의 제조, 발현 및 해석
Beidler et al. Generation and activity of a humanized monoclonal antibody that selectively neutralizes the epidermal growth factor receptor ligands transforming growth factor-α and epiregulin
CN104011206A (zh) 新型抗人ctgf抗体
CA3236646A1 (en) Novel anti-l1cam antibody
KR20140066785A (ko) 항-연장된 ⅰ형 글라이코스핑고지질 항체, 이의 유도체 및 용도
RU2790023C2 (ru) Способы лечения заболевания с применением ингибиторов костного морфогенетического белка 6 (вмр6)
CN117098773A (zh) 特异于冠状病毒刺突蛋白的抗体及其用途
KR20220061903A (ko) 코로나바이러스 스파이크 단백질에 특이적인 항체 및 이의 용도

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid